Genentech raises stakes on PARP inhibitors

Article Abstract:

Genetech, based in South San Francisco, California which has entered the area of the poly (ADP-Ribose) polymerase (PARP) disclosed on July 25, 2006 that it had entered a drug development agreement with Massachusetts-based Inotek Pharmaceuticals. Under the deal, Inotek is receiving an upfront payment of $20 million plus up to $405 million in milestone payments and royalties on eventual product sales in return for outlicensing oncology applications of its lead compound, PARP inhibitor INO-1001, plus, its next-generation successors.

Product development, Science & research, Drugs, Alliances, partnerships, United States, Drug therapy, Biological products industry, Pfizer Inc., Genentech Inc., Cancer, PFE, Adenosine diphosphate, DNA, Research agreements, Inotek Pharmaceuticals Corp.

---

European pharma consolidation generates quality spinoffs

Article Abstract:

Bayer Healthcare acquires Berlin based Schering and the restructuring of Bayer resulted in two new German spinoffs AiCuris of Wuppertal and Intermed Discovery of Dortmund. The new pharma spinoffs, though would need many years before they successfully attain maturity, they have the kind of head start that takes them beyond the growing pains that most of the start-up companies face.

Acquisitions & mergers, Organizational history, Germany, Mergers, acquisitions and divestments, Company acquisition/merger, Company restructuring/company reorganization, Reorganization and restructuring, Schering AG, Company organization, Bayer HealthCare AG

---

EMEA struggles with need to restructure

Article Abstract:

A drug discovery firm PharmaMar appeals to change the role of European Agency for the Evaluation of Medicinal Products (EMEA) in a number of ways. The restructure of EMEA would introduce more flexibility and transparency to its dealing with the drug companies and the public.

Management dynamics, Spain, Management, Powers and duties, Company business management, European Agency for the Evaluation of Medicinal Products, PharmaMar

Similar abstracts:

• Abstracts: Pentagon grant targets mustard gas. European nations should strengthen militaries through integration
• Abstracts: IRS issues welcome guidelines regarding relief for late S corporation - related elections. K-1 matching program continues
• Abstracts: McIntosh to answer questions. Limits placed on UK 'super casinos'. Germany: a new horizon?
• Abstracts: Ireland launches regenerative medicine research center. China steps up US biotech intellectual property land grab

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.